Abassi Z A, Pieruzzi F, Nakhoul F, Keiser H R
Hypertension-Endocrine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1754, USA.
Hypertension. 1996 May;27(5):1140-8. doi: 10.1161/01.hyp.27.5.1140.
Increasing evidence suggests that endothelin, a potent vasoconstrictor, is implicated in cyclosporin A (CsA)-induced nephrotoxicity. Increased levels of urinary and circulating endothelin have been described in CsA-treated humans and animals. The exact mechanisms by which CsA induces these increases are still unknown, and no data indicate whether these elevated levels reflect increased synthesis or decreased clearance of endothelin. In the present study, we investigated the effects of CsA administration (50 mg/kg per day i.p. for 6 days) to rats on plasma and urinary levels of endothelin; expression of endothelin-1 (ET-1), ET-3, and endothelin-converting enzyme in renal tissue; clearance of infused 125I-ET-1; and degradation of 125I-ET-1 by recombinant neutral endopeptidase. Rats given CsA for 6 days developed severe renal insufficiency, as shown by a 74% decrease in creatinine clearance rate (Ccr) (P < .006). Ccr was remarkably improved in CsA-treated rats that received bosentan, the combined antagonist of both endothelin A and endothelin B receptors. Urinary excretion of endothelin increased from an undetectable level to 31.7 +/- 6.0 pg/24 h (P < .001), and plasma levels of endothelin were unchanged (2.8 +/- 0.2 to 3.1 +/- 0.2 pg/mL). Reverse transcription followed by quantitative polymerase chain reaction revealed that ET-1 mRNA in the renal medulla increased by 59% (P < .006), whereas the expression of both ET-3 and endothelin-converting enzyme was unchanged. In other rats, neither acute nor chronic treatment with CsA affected either the clearance of 125I-ET-1 from the blood or the renal and pulmonary uptake of the peptide. Moreover, CsA did not affect the degradation of 125I-ET-1 by highly purified recombinant neutral endopeptidase, a well-known endothelinase. Taken together, these data suggest that the elevated urinary endothelin levels obtained after CsA treatment originate from the kidney and reflect increased renal synthesis of ET-1. Moreover, the production of endothelin appears to be regulated at the mRNA transcription level, and expressions of ET-1 and ET-3 are regulated independently.
越来越多的证据表明,内皮素作为一种强效血管收缩剂,与环孢素A(CsA)诱导的肾毒性有关。在接受CsA治疗的人和动物中,已发现尿液和循环中的内皮素水平升高。CsA导致这些升高的确切机制仍不清楚,且尚无数据表明这些升高的水平反映的是内皮素合成增加还是清除减少。在本研究中,我们调查了给大鼠腹腔注射CsA(每天50mg/kg,持续6天)对血浆和尿液中内皮素水平的影响;肾组织中内皮素-1(ET-1)、ET-3和内皮素转换酶的表达;注入的125I-ET-1的清除;以及重组中性内肽酶对125I-ET-1的降解。给予CsA 6天的大鼠出现严重肾功能不全,肌酐清除率(Ccr)降低74%(P <.006)。接受波生坦(内皮素A和内皮素B受体的联合拮抗剂)治疗的CsA处理大鼠的Ccr显著改善。内皮素的尿排泄量从检测不到的水平增加到31.7±6.0 pg/24小时(P <.001),而血浆内皮素水平未变(2.8±0.2至3.1±0.2 pg/mL)。逆转录后进行定量聚合酶链反应显示,肾髓质中的ET-1 mRNA增加了59%(P <.006),而ET-3和内皮素转换酶的表达未变。在其他大鼠中,CsA的急性或慢性治疗均未影响125I-ET-1从血液中的清除或该肽在肾脏和肺部的摄取。此外,CsA不影响高度纯化的重组中性内肽酶(一种著名的内皮素酶)对125I-ET-1的降解。综上所述,这些数据表明,CsA治疗后尿液中内皮素水平升高源自肾脏,反映了ET-1的肾脏合成增加。此外,内皮素的产生似乎在mRNA转录水平受到调节,且ET-1和ET-3的表达是独立调节的。